Our previous study demonstrated that the expression of CD200 and CD200R1 is higher and lower, respectively, in DCs, including both pDCs and mDCs, in patients with SLE compared with healthy controls, which may contribute to immunologic abnormalities and can be corrected by CD200-Fc treatment through reducing DC migration in patients with SLE16. The gene discussed is CD200R1; the disease is systemic lupus erythematosus.